APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuropathy Pain Treatment

This report studies the Neuropathy Pain Treatment market,

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

This report studies the Neuropathy Pain Treatment market,

Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathy Pain Treatment is used for Neuropathic pain.

Selected research

Market Outlook & Growth Opportunities

Global Neuropathy Pain Treatment Market Outlook and Growth Opportunities 2026

25 December 2025193 pages

Choose your research edition.

Industry ResearchNeuropathy Pain Treatment Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuropathy Pain Treatment Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Neuropathy Pain Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuropathy Pain Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuropathy Pain Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

This report studies the Neuropathy Pain Treatment market,

Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathy Pain Treatment is used for Neuropathic pain.

Global Neuropathy Pain Treatment key players include Eli Lilly, Pfizer, etc. Global top two manufacturers hold a share over 65%.

Read the full market overview

North America is the largest market, with a share about 45%, followed by Asia-Pacific and Europe, both have a share about 50 percent.

In terms of product, Calcium channel alpha 2-delta ligands is the largest segment, with a share about 70%. And in terms of application, the largest application is Retail Pharmacies, followed by Hospitals, etc.

This report provides an overview of the global Neuropathy Pain Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuropathy Pain Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuropathy Pain Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neuropathy Pain Treatment market.

Neuropathy Pain Treatment Segment by Company

Pfizer

Depomed

Eli Lilly

Endo

Grünenthal Group

Arbor Pharmaceuticals

Neuropathy Pain Treatment Segment by Type

Calcium Channel Alpha 2-delta Ligands

Serotonin-norepinephrine Reuptake Inhibitors

Others

Neuropathy Pain Treatment Segment by Application

Retail Pharmacies

Hospitals

Others

Neuropathy Pain Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuropathy Pain Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neuropathy Pain Treatment key companies, revenue, market share, and recent developments.

3. To split the Neuropathy Pain Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neuropathy Pain Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuropathy Pain Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Neuropathy Pain Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuropathy Pain Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuropathy Pain Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuropathy Pain Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuropathy Pain Treatment industry.

Chapter 3: Detailed analysis of Neuropathy Pain Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neuropathy Pain Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neuropathy Pain Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuropathy Pain Treatment Industry Trends Table 2. Neuropathy Pain Treatment Industry Drivers Table 3. Neuropathy Pain Treatment Industry Opportunities and Challenges Table 4. Neuropathy Pain Treatment Industry Restraints Table 5. Global Neuropathy Pain Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuropathy Pain Treatment Revenue Share by Company (2021-2026) Table 7. Global Neuropathy Pain Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neuropathy Pain Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Neuropathy Pain Treatment Company, Product Type & Application Table 10. Global Neuropathy Pain Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neuropathy Pain Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Calcium Channel Alpha 2-delta Ligands Table 15. Significant Companies of Serotonin-norepinephrine Reuptake Inhibitors Table 16. Significant Companies of Others Table 17. Global Neuropathy Pain Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Neuropathy Pain Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Neuropathy Pain Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Neuropathy Pain Treatment Sales Value Share by Type (2021-2026) Table 21. Global Neuropathy Pain Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Retail Pharmacies Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Others Table 25. Global Neuropathy Pain Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuropathy Pain Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Neuropathy Pain Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Neuropathy Pain Treatment Sales Value Share by Application (2021-2026) Table 29. Global Neuropathy Pain Treatment Sales Value Share by Application (2027-2032) Table 30. Global Neuropathy Pain Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neuropathy Pain Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Neuropathy Pain Treatment Sales Value Share by Region (2021-2026) Table 33. Global Neuropathy Pain Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Neuropathy Pain Treatment Sales Value Share by Region (2027-2032) Table 35. Global Neuropathy Pain Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neuropathy Pain Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Neuropathy Pain Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Neuropathy Pain Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Neuropathy Pain Treatment Sales Value Market Share by Country (2027-2032) Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Neuropathy Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Pfizer Neuropathy Pain Treatment Product Portfolio Table 44. Pfizer Recent Development Table 45. Depomed Company Information Table 46. Depomed Business Overview Table 47. Depomed Neuropathy Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Depomed Neuropathy Pain Treatment Product Portfolio Table 49. Depomed Recent Development Table 50. Eli Lilly Company Information Table 51. Eli Lilly Business Overview Table 52. Eli Lilly Neuropathy Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Eli Lilly Neuropathy Pain Treatment Product Portfolio Table 54. Eli Lilly Recent Development Table 55. Endo Company Information Table 56. Endo Business Overview Table 57. Endo Neuropathy Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Endo Neuropathy Pain Treatment Product Portfolio Table 59. Endo Recent Development Table 60. Grünenthal Group Company Information Table 61. Grünenthal Group Business Overview Table 62. Grünenthal Group Neuropathy Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Grünenthal Group Neuropathy Pain Treatment Product Portfolio Table 64. Grünenthal Group Recent Development Table 65. Arbor Pharmaceuticals Company Information Table 66. Arbor Pharmaceuticals Business Overview Table 67. Arbor Pharmaceuticals Neuropathy Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Arbor Pharmaceuticals Neuropathy Pain Treatment Product Portfolio Table 69. Arbor Pharmaceuticals Recent Development Table 70. Research Programs/Design for This Report Table 71. Authors List of This Report Table 72. Secondary Sources Table 73. Primary Sources List of Figures Figure 1. Neuropathy Pain Treatment Product Image Figure 2. Global Neuropathy Pain Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuropathy Pain Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuropathy Pain Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Calcium Channel Alpha 2-delta Ligands Image Figure 8. Serotonin-norepinephrine Reuptake Inhibitors Image Figure 9. Others Image Figure 10. Global Neuropathy Pain Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Neuropathy Pain Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Neuropathy Pain Treatment Sales Value Share by Type (2021-2032) Figure 13. Retail Pharmacies Image Figure 14. Hospitals Image Figure 15. Others Image Figure 16. Global Neuropathy Pain Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neuropathy Pain Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neuropathy Pain Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Neuropathy Pain Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Neuropathy Pain Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Neuropathy Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Neuropathy Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Neuropathy Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Neuropathy Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Neuropathy Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Neuropathy Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Neuropathy Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Neuropathy Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Neuropathy Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Neuropathy Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Channel Alpha 2-delta Ligands
  • Serotonin-norepinephrine Reuptake Inhibitors
  • Others
Applications
  • Retail Pharmacies
  • Hospitals
  • Others
Companies covered
  • Pfizer
  • Depomed
  • Eli Lilly
  • Endo
  • Grünenthal Group
  • Arbor Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuropathy Pain Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuropathy Pain Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neuropathy Pain Treatment Market Dynamics
  1. 2.1 Neuropathy Pain Treatment Industry Trends
  2. 2.2 Neuropathy Pain Treatment Industry Drivers
  3. 2.3 Neuropathy Pain Treatment Industry Opportunities and Challenges
  4. 2.4 Neuropathy Pain Treatment Industry Restraints
3 Neuropathy Pain Treatment Market by Company
  1. 3.1 Global Neuropathy Pain Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Neuropathy Pain Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Neuropathy Pain Treatment Company Ranking (2024-2026)
  4. 3.4 Global Neuropathy Pain Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Neuropathy Pain Treatment Company Product Type and Application
  6. 3.6 Global Neuropathy Pain Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neuropathy Pain Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neuropathy Pain Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neuropathy Pain Treatment Market by Type
  1. 4.1 Neuropathy Pain Treatment Type Introduction
  2. 4.1.1 Calcium Channel Alpha 2-delta Ligands
  3. 4.1.2 Serotonin-norepinephrine Reuptake Inhibitors
  4. 4.1.3 Others
  5. 4.2 Global Neuropathy Pain Treatment Sales Value by Type
  6. 4.2.1 Global Neuropathy Pain Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuropathy Pain Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Neuropathy Pain Treatment Sales Value Share by Type (2021-2032)
5 Neuropathy Pain Treatment Market by Application
  1. 5.1 Neuropathy Pain Treatment Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospitals
  4. 5.1.3 Others
  5. 5.2 Global Neuropathy Pain Treatment Sales Value by Application
  6. 5.2.1 Global Neuropathy Pain Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuropathy Pain Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Neuropathy Pain Treatment Sales Value Share by Application (2021-2032)
6 Neuropathy Pain Treatment Regional Value Analysis
  1. 6.1 Global Neuropathy Pain Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuropathy Pain Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neuropathy Pain Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neuropathy Pain Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuropathy Pain Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Neuropathy Pain Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neuropathy Pain Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Neuropathy Pain Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neuropathy Pain Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neuropathy Pain Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neuropathy Pain Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Neuropathy Pain Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neuropathy Pain Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neuropathy Pain Treatment Sales Value Share by Country, 2025 VS 2032
7 Neuropathy Pain Treatment Country-level Value Analysis
  1. 7.1 Global Neuropathy Pain Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuropathy Pain Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neuropathy Pain Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neuropathy Pain Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neuropathy Pain Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neuropathy Pain Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neuropathy Pain Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Neuropathy Pain Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Neuropathy Pain Treatment Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Depomed
  8. 8.2.1 Depomed Company Information
  9. 8.2.2 Depomed Business Overview
  10. 8.2.3 Depomed Neuropathy Pain Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Depomed Neuropathy Pain Treatment Product Portfolio
  12. 8.2.5 Depomed Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Neuropathy Pain Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Neuropathy Pain Treatment Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Endo
  20. 8.4.1 Endo Company Information
  21. 8.4.2 Endo Business Overview
  22. 8.4.3 Endo Neuropathy Pain Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Endo Neuropathy Pain Treatment Product Portfolio
  24. 8.4.5 Endo Recent Developments
  25. 8.5 Grünenthal Group
  26. 8.5.1 Grünenthal Group Company Information
  27. 8.5.2 Grünenthal Group Business Overview
  28. 8.5.3 Grünenthal Group Neuropathy Pain Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Grünenthal Group Neuropathy Pain Treatment Product Portfolio
  30. 8.5.5 Grünenthal Group Recent Developments
  31. 8.6 Arbor Pharmaceuticals
  32. 8.6.1 Arbor Pharmaceuticals Company Information
  33. 8.6.2 Arbor Pharmaceuticals Business Overview
  34. 8.6.3 Arbor Pharmaceuticals Neuropathy Pain Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Arbor Pharmaceuticals Neuropathy Pain Treatment Product Portfolio
  36. 8.6.5 Arbor Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst